|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
FDA’s New Biosimilars Plan: What’s the Deal With the Agency’s New Policy and What’s the Impact on Pharmaceutical Stakeholders
To date 12 biosimilar products have been approved by the FDA — but only 3 have reached the market.
The FDA’s Biosimilars Action Plan:
FDAnews has enlisted the help of consultant Nitisha Pyndiah to spell out what you need to know — what the FDA is thinking, where the industry is heading, and how you can gain competitive advantage. Here are just a few of the specifics to be covered:
You need to understand the FDA’s action plan and how it will affect your biosimilar product development. Order today to get an insight into the different stakeholders opinion.
Nitisha Pyndiah Ph.D. is a consultant with HartmannWillner where she provides Biotech Consulting Services to clients, including strategic support for development of biological, biotechnologica, and biosimilar products from preclinical development through the entire product lifecycle.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing